Trials / Unknown
UnknownNCT02049125
Study of Accuracy of NGAL, a Renal Injury Biomarker, in Patients With Cirrhosis
Urinary Biomarker NGAL in Decompensated Cirrhosis: Early Prediction of AKI and of Treatment Response
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 300 (estimated)
- Sponsor
- University of Sao Paulo · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to test the accuracy of urinary neutrophil-gelatinase associated lipocalin (NGAL) and other biomarkers (plasma renin, norepinephrine) to predict acute kidney injury (AKI) development in patients with cirrhosis and bacterial infection and to predict response to AKI treatment with albumin and albumin with terlipressin in patients with suspected hepatorenal syndrome.
Conditions
Timeline
- Start date
- 2013-06-01
- Primary completion
- 2017-12-01
- Completion
- 2018-03-01
- First posted
- 2014-01-29
- Last updated
- 2016-10-27
Locations
4 sites across 1 country: Brazil
Source: ClinicalTrials.gov record NCT02049125. Inclusion in this directory is not an endorsement.